See What HealthDay Can Do For You
Contact Us

Drug Combo Tolerated in Younger Children With Cystic Fibrosis

Lumacaftor/ivacaftor safe in children ages 2 to 5 with cystic fibrosis homozygous for F508del-CFTR

child checkup

THURSDAY, Feb. 7, 2019 (HealthDay News) -- Lumacaftor/ivacaftor treatment is generally safe and well tolerated for children aged 2 to 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation, according to a study published online Jan. 24 in The Lancet Respiratory Medicine.

John J. McNamara, M.D., from Children's Minnesota in Minneapolis, and colleagues enrolled children aged 2 to 5 years weighing ≥8 kg at enrollment who had a confirmed diagnosis of CF homozygous for the F508del-CFTR mutation in an open-label phase 3 study. Patients received lumacaftor 100 mg/ivacaftor 125 mg (body weight <14 kg) or lumacaftor 150 mg/ivacaftor 188 mg (body weight ≥14 kg) orally for 15 days in part A (12 children) and for 24 weeks in part B (60 children).

The researchers found that safety and pharmacokinetics were consistent with the known safety profile. In part B, 98.3 percent of children had one or more treatment-emergent adverse events (AEs); most were of mild-to-moderate severity. The most common AEs were cough, vomiting, pyrexia, and rhinorrhea. Four children experienced serious AEs: infective pulmonary exacerbation of CF, viral gastroenteritis, and constipation. Because of elevated transaminases, 5 percent of the children discontinued treatment. At week 24, there was a 31.7 mmol/L decrease in mean sweat chloride concentrations, improvement in biomarkers of pancreatic function, and increases in growth parameters.

"These data highlight the potential of early intervention with lumacaftor/ivacaftor to improve clinically relevant outcomes," the authors write.

Several authors are employees of and disclosed financial ties to Vertex Pharmaceuticals, which manufactures lumacaftor/ivacaftor and funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.